A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
2010年10月8日 更新者:Pfizer
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
To assess the safety and efficacy of SU011248 in patients with metastatic, refractory renal cell carcinoma
研究概览
研究类型
介入性
注册 (实际的)
106
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
California
-
Duarte、California、美国、91010-3000
- Pfizer Investigational Site
-
Pasadena、California、美国、91105
- Pfizer Investigational Site
-
San Francisco、California、美国、94115
- Pfizer Investigational Site
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- Pfizer Investigational Site
-
Boston、Massachusetts、美国、02115
- Pfizer Investigational Site
-
Boston、Massachusetts、美国、02215
- Pfizer Investigational Site
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- Pfizer Investigational Site
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- Pfizer Investigational Site
-
-
New York
-
New York、New York、美国、10021
- Pfizer Investigational Site
-
New York、New York、美国、10022
- Pfizer Investigational Site
-
-
North Carolina
-
Durham、North Carolina、美国、27705
- Pfizer Investigational Site
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- Pfizer Investigational Site
-
-
Oregon
-
Portland、Oregon、美国、97213
- Pfizer Investigational Site
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19111
- Pfizer Investigational Site
-
-
Wisconsin
-
Madison、Wisconsin、美国、53792
- Pfizer Investigational Site
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Cytokine refractory metastatic renal cell carcinoma with clear cell component
- Radiographic evidence of disease progression during or within 9 months of completion of 1 cytokine therapy
- Prior nephrectomy
Exclusion Criteria:
- Prior treatment with any systemic therapy other than 1 cytokine therapy
- History of or known brain metastases
- Uncontrolled hypertension or other significant cardiac events within the 12 months prior to study start
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:1个
|
50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Subjects With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)
大体时间:From start of study treatment until Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter
|
Overall confirmed objective response = confirmed Complete Response (CR) or confirmed Partial Response (PR) according to RECIST.
CR defined as disappearance of all target lesions.
PR defined as >= 30 percent decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
|
From start of study treatment until Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to Tumor Progression (TTP)
大体时间:From start of study treatment until Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter
|
Time in weeks from start of study treatment to first documentation of objective tumor progression or death due to cancer, whichever comes first.
TTP was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]).
|
From start of study treatment until Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter
|
|
Duration of Response (DR)
大体时间:Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter or death due to cancer
|
Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7. DR was calculated for the subgroup of patients with a confirmed objective tumor response. |
Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter or death due to cancer
|
|
Overall Survival (OS)
大体时间:From start of study treatment until death
|
Time in weeks from the start of study treatment to date of death due to any cause.
OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 7. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the subject current status was death).
|
From start of study treatment until death
|
|
Progression-free Survival (PFS)
大体时间:From start of study treatment until Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter or death
|
Time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause.
PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was "Death").
|
From start of study treatment until Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter or death
|
|
Percent Chance of Patient Survival
大体时间:From start of study treatment until death
|
Probability of survival 1 year and 2 years after the first dose of study treatment
|
From start of study treatment until death
|
|
Observed Plasma Trough Concentrations of Sunitinib
大体时间:Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
Observed plasma trough (predose) (Cmin) concentrations of sunitinib
|
Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
|
Observed Plasma Trough Concentrations of Sunitinib Metabolite
大体时间:Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
Observed plasma trough (predose) (Cmin) concentrations of sunitinib metabolite (SU012662)
|
Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
|
Observed Plasma Trough Concentrations of Sunitinib Plus Metabolite
大体时间:Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
Observed plasma trough (predose) concentrations of sunitinib plus its metabolite (SU012662)
|
Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
|
Dose Corrected Plasma Trough Concentrations of Sunitinib
大体时间:Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
Dose corrected plasma trough (predose) (Cmin) concentrations of sunitinib.
Dose-corrected trough concentrations were set to missing for trough samples collected outside acceptable times from dose administration, samples not collected within scheduled day range, samples with missing collection or administration dates or times, samples collected with dose interruption, and samples collected with inconsistent dose level within 10 days of last dose date.
|
Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
|
Dose Corrected Plasma Trough Concentrations of Sunitinib Metabolite
大体时间:Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
Dose corrected plasma trough (predose) (Cmin) concentrations of sunitinib metabolite (SU012662).
Dose-corrected trough concentrations were set to missing for trough samples collected outside acceptable times from dose administration, samples not collected within scheduled day range, samples with missing collection or administration dates or times, samples collected with dose interruption, and samples collected with inconsistent dose level within 10 days of last dose date.
|
Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
|
Dose Corrected Plasma Trough Concentrations of Sunitinib Plus Metabolite
大体时间:Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
Dose corrected plasma trough (predose) (Cmin) concentrations of sunitinib plus its metabolite (SU012662).
Dose-corrected trough concentrations were set to missing for trough samples collected outside acceptable times from dose administration, samples not collected within scheduled day range, samples with missing collection or administration dates or times, samples collected with dose interruption, and samples collected with inconsistent dose level within 10 days of last dose date.
|
Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
赞助
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21.
- Grunwald V, Lin X, Kalanovic D, Simantov R. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. Eur Urol. 2016 Dec;70(6):1006-1015. doi: 10.1016/j.eururo.2016.05.010. Epub 2016 May 26.
- Grunwald V, McKay RR, Krajewski KM, Kalanovic D, Lin X, Perkins JJ, Simantov R, Choueiri TK. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol. 2015 May;67(5):952-8. doi: 10.1016/j.eururo.2014.12.036. Epub 2015 Jan 7.
- Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006 Jun 7;295(21):2516-24. doi: 10.1001/jama.295.21.2516.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2004年2月1日
初级完成 (实际的)
2008年9月1日
研究完成 (实际的)
2008年9月1日
研究注册日期
首次提交
2004年2月13日
首先提交符合 QC 标准的
2004年2月17日
首次发布 (估计)
2004年2月18日
研究记录更新
最后更新发布 (估计)
2010年10月13日
上次提交的符合 QC 标准的更新
2010年10月8日
最后验证
2010年10月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.